Cellares and ProTgen Automate Manufacturing of Progenitor T-Cell Therapy for Blood Cancer

The partnership will automate manufacturing and quality control of ProT-096, ProTgen’s personalized progenitor T-cell therapy for refractory leukemia and other hematologic malignancies. Cellares will also provide regulatory support toward IND submission.   The post Cellares and ProTgen Automate Manufacturing of Progenitor T-Cell Therapy for Blood Cancer appeared first on GEN - Genetic Engineering and Biotechnology News .